Phase III Trials Will Advance Lanifibranor For MASH Treatment

Published
02 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
€6.20
38.7% undervalued intrinsic discount
15 Aug
€3.80
Loading
1Y
65.9%
7D
26.7%

Author's Valuation

€6.2

38.7% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 1.43%

Shared on24 Apr 25
Fair value Increased 4.49%

AnalystConsensusTarget has decreased revenue growth from -2.0% to -0.5% and increased discount rate from 6.4% to 7.0%.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 2.90%

AnalystConsensusTarget has decreased revenue growth from 57.8% to -2.0%, increased profit margin from 15.6% to 17.6%, increased future PE multiple from 149.7x to 363.5x and decreased shares outstanding growth rate from 0.3% to 0.1%.